Cargando…
The Alzheimer’s Prevention Initiative Composite Cognitive Test: a practical measure for tracking cognitive decline in preclinical Alzheimer’s disease
BACKGROUND: There is growing interest in identifying sensitive composite cognitive tests to serve as primary endpoints in preclinical Alzheimer’s disease (AD) treatment trials. We reported previously a composite cognitive test score sensitive to tracking preclinical AD decline up to 5 years prior to...
Autores principales: | Langbaum, Jessica B., Ellison, Noel N., Caputo, Angelika, Thomas, Ronald G., Langlois, Carolyn, Riviere, Marie-Emmanuelle, Graf, Ana, Lopez Lopez, Cristina, Reiman, Eric M., Tariot, Pierre N., Hendrix, Suzanne B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7254761/ https://www.ncbi.nlm.nih.gov/pubmed/32460855 http://dx.doi.org/10.1186/s13195-020-00633-2 |
Ejemplares similares
-
The Alzheimer's Prevention Initiative Generation Program: Study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer's disease
por: Lopez Lopez, Cristina, et al.
Publicado: (2019) -
Rationale for the selection of dual primary endpoints in prevention studies of cognitively unimpaired individuals at genetic risk for developing symptoms of Alzheimer’s disease
por: Caputo, Angelika, et al.
Publicado: (2023) -
Alzheimer's Prevention Initiative Generation Program: Development of an APOE genetic counseling and disclosure process in the context of clinical trials
por: Langlois, Carolyn M., et al.
Publicado: (2019) -
Measuring cognition and function in the preclinical stage of Alzheimer's disease
por: Weintraub, Sandra, et al.
Publicado: (2018) -
The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer's disease, including a placebo-treated noncarrier cohort
por: Tariot, Pierre N., et al.
Publicado: (2018)